Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 3 of 16

  1. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  2. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  3. MGL-3196-11

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  4. MGL-3196-19

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  5. MHICC-2021-001

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  6. Maridebart cafraglutide

    Amgen

    Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

    phase 3 small molecule active

    1 trial

  7. Metformin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  8. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  9. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  10. Mibavademab

    Regeneron UK Limited

    Monogenic Obesity

    phase 3 small molecule active

    1 trial

  11. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  12. N1T-MC-MALO

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  13. NN1436-7724

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. NN1436-8182

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  15. NN1535-8377

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  16. NN8022-4392

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  17. NN9388-4895

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  18. NN9388-7637

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  19. NN9388-7741

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  20. NN9490-8021

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  21. NN9490-8024

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  22. NN9490-8025

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  23. NN9490-8026

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  24. NN9490-8028

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  25. NN9490-8266

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  26. NN9490-8293

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  27. NN9490-8294

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  28. NN9490-8559

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  29. NN9535-4352

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  30. NN9833-8242

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  31. NN9833-8243

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  32. NN9838-4608

    NovoThirteen

    Overweight and obesity

    phase 3 other active

    1 trial

  33. NN9838-4609

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  34. NN9838-7749

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  35. NN9838-7859

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  36. NN9924-4437

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  37. NN9931-4553

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  38. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  39. OBEZ-303

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  40. OPC-262

    KYOWA KIRIN AUSTRALIA PTY LTD

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  41. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

  42. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 3 small molecule active

    2 trials

  43. ORMD-0801 (qd)

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  44. ORMD-0801 8 mg

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  45. Oral semaglutide

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  46. Orforglipron

    Eli Lilly and Company

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  47. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  48. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.